1Pera M, Cameron A T, Trastek V F. increasing incident of adenoearcinoma of the esophagus and esophagogastric junction [J]. Gastroenterology, 1993, 104: 510.
5Peghini P L, Katz P O, Castelt D O. Ranitidine controls nocturnal gastric acid breakthrough on omeprazole: a controlled study in normal subjects[J]. Gastroenterology, 1998, 115: 1335.
3Vakil N, van Zanten SV, Kahrilas P, et al; Global Consensus Group. The Montreal definition and classification of gastroesophageal reflux disease: a global evidence-based consensus. Am J Gastroenterol, 2006, 101 (8): 1900-1920.
4Dent J, E1-Serag HB, Wallander MA, et al. Epidemiology of gastro-oesophageal reflux disease: a systematic review. Gut, 2005, 54 (5): 710-717.
5Wong BC, Kinoshita Y. Systematic review on epidemiology of gastroesophageal reflux disease in Asia. Clin Gastroenterol Hepatol, 2006, 4 (4): 398-407.
6Chert M, Xiong L, Chert H, et al. Prevalence, risk factors and impact of gastroesophageal reflux disease symptoms: a population-based study in South China. Scand J Gastroenterol, 2005, 40 (7): 759-767.
7Moss SF, Armstrong D, Arnold R, et al. GERD 2003 -- a consensus on the way ahead. Digestion, 2003, 67 (3): 111-117.
8Omari TI, Barnett CP, Benninga MA, et al. Mechanisms of gastro-oesophageal reflux in preterm and term infants with reflux disease. Gut, 2002, 51 (4): 475-479.
9Wong WM, Lai KC, Hui WM, et al. Pathophysiology of gastroesophageal reflux diseases in Chinese -- role of transient lower esophageal sphincter relaxation and esophageal motor dysfunction. Am J Gastroenterol, 2004, 99 (11): 2088-2093.
10Rossiter A, Guelrud M, Souney PF, et al. High vasoactive intestinal polypeptide plasma levels in patients with Barrett's esophagus. Scand J Gastroenterol, 1991, 26 (5): 572-576.
